Effects of intermedin1-53 on myocardial fibrosis

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 2, 2013, Pages 141-148

  Yang, Xiaoling ^a   Zhang, Huiping ^a   Jia, Yuexia ^a   Ni, Lan ^a   Li, Guizhong ^a   Xue, Lihua ^a   Jiang, Yideng ^a  

^a NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Aldosterone; Calcitonin gene related peptide; Cardiac fibroblast; Intermedin1 53

Indexed keywords

ADRENOMEDULLIN; INTERMEDIN PROTEIN, RAT; NEUROPEPTIDE;

ANIMAL; ARTICLE; CELL CULTURE; FIBROBLAST; HEART MUSCLE; HEART MUSCLE FIBROSIS; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADRENOMEDULLIN; ANIMALS; CELLS, CULTURED; ENDOMYOCARDIAL FIBROSIS; FIBROBLASTS; MALE; MYOCARDIUM; NEUROPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

MLCS; MLOWN;

EID: 84881258326     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms093     Document Type: Article

References (27)

1. Creemers EE and Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89: 265-272.
2. Chang CL, Roh J and Hsu SY. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: a comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 2004, 25: 1633-1642.
3. Roh J, Chang CL, Bhalla A, Klein C and Hsu SY. Intermedin is a calcitonin/ calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004, 279: 7264-7274.
4. Cottrell GS, Alemi F, Kirkland JG, Grady EF, Corvera CU and Bhargava A. Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract. Peptides 2012, 35: 202-211.
5. Pfeil U, Aslam M, Paddenberg R, Quanz K, Chang CL, Park JI and Gries B, et al. Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability. Am J Physiol Lung Cell Mol Physiol 2009, 297: L837-L845.
6. Egbert B, Gero T, Paul B, Burkhard S, Sebastian B, von Dirk L and Burkert P. Atrial myocardium is the predominant inotropic target of adrenomedullin in the human heart. Am J Physiol Heart Circ Physiol 2007, 293: H3001-H3007.
7. Zeng Q, Yuan Y, Wang X, Wu HM, Fan L, Qi YF and Tang CS, et al. Upregulated expression of intermedin and its receptor in the myocardium and aorta in spontaneously hypertensive rats. Peptides 2009, 30: 391-399.
8. Hay DL, Conner AC, Howitt SG, Smith DM and Poyner DR. The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors. J Mol Neurosci 2004, 22: 105-113.
9. Pan CS, Yang JH, Cai DY, Zhao J, Gerns H, Yang J and Chang JK, et al. Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2. Peptides 2005, 26: 1640-1646.
10. Hagiwara M, Bledsoe G, Yang ZR, Smith RS Jr, Chao L and Chao J. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol 2008, 295: F1735-F1743.
11. Song JQ, Teng X, Cai Y, Tang CS and Qi YF. Activation of Akt/ GSK-3beta signaling pathway is involved in intermedin (1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 2009, 14: 1299-1307.
12. Teng X, Song J, Zhang G, Cai Y, Yuan F, Du J and Tang C, et al. Inhibition of endoplasmic reticulum stress by intermedin (1-53) protects against myocardial injury through a PI3 kinase-Akt signaling pathway. J Mol Med (Berl) 2011, 89: 1195-1205.
13. Bell D, Campbell M, Ferguson M, Sayers L, Donaghy L, O'Regan A and Jewhurst V, et al. AM-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury. J Physiol 2012, 590: 1181-1197.
14. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H and Miyano S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett 2004, 556: 53-58.
15. Yang JH, Pan CS, Jia YX, Zhang J, Zhao J, Pang YZ and Yang J, et al. Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Biochem Biophys Res Commun 2006, 341: 567-572.
16. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961, 93: 440-447.
17. Krenning G, Zeisberg EM and Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225: 631-637.
18. Boccanelli A and Battagliese A. Effects of aldosterone receptor blocker therapy on cardiac remodeling. G Ital Nefrol 2006, 34: S57-S63.
19. Horký K. Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management. Vnitr Lek 2011, 57: 1012-1016.
20. Vogt B and Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep 2009, 11: 450-455.
21. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA and Cachofeiro V, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 2011, 301: H2372-H2382.
22. Zhao L, Peng DQ, Zhang J, Song JQ, Teng X, Yu YR and Tang CS, et al. Extracellular signal-regulated kinase 1/2 activation is involved in intermedin1- 53 attenuating myocardial oxidative stress injury induced by ischemia/ reperfusion. Peptides 2012, 33: 329-335.
23. Taylor MM, Bagley SL and Samson WK. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. Am J Physiol Regul Integr Comp Physiol 2005, 288: R919-R927.
24. Ren YS, Yang JH, Zhang J, Pan CS, Yang J, Zhao J and Pang YZ, et al. Intermedin 1-53 in central nervous system elevates arterial blood pressure in rats. Peptides 2006, 27: 74-79.
25. Pearson LJ, Yandle TG, Nicholls MG and Evans JJ. Intermedin (adrenomedullin-2): a potential protective role in human aortic endothelial cells. Cell Physiol Biochem 2009, 23: 97-108.
26. Hirose T, Totsune K, Mori N, Morimoto R, Hashimoto M, Nakashige Y and Metoki H, et al. Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure. Eur J Heart Fail 2008, 10: 840-849.
27. Robinson SD, Aitken JF, Bailey RJ, Poyner DR and Hay DL. Novel peptide antagonists of adrenomedullin and calcitonin gene-related peptide receptors: identification, pharmacological characterization, and interactions with position 74 in receptor activity-modifying protein 1/3. J Pharmacol Exp Ther 2009, 331: 513-521.